Member Info for evman27

Https://x.com/Share_Talk/status/1946163704988414314

07:19 onwards.

The antibody market is rapidly growing.

The global antibody therapeutics market was valued around US $135B in 2018 and is forecast to exceed US $300B by 2025.

In 2024, Adrian, 'highlighted the importance of antibodies in therapeutics, noting that in 2023, 12 out of 17 approved protein drugs were antibodies.'

'Kinkaid mentioned the company's expansion into veterinary medicine and diagnostics. He noted the growing traction in these areas, particularly in diagnostics where antibodies play a crucial role.'

Source - https://www.proactiveinvestors.co.uk/companies/news/1049097/fusion-antibodies-ceo-highlights-strategic-growth-and-innovations-one2one-investor-forum-1049097.html

In reference to GTCs post, here is the patent link to save you finding it on previous pages.

https://patentcenter.uspto.gov/applications/17287441/ifw/docs?application=

Wouldn’t want to be out of this over the weekend 😉

Allenby broker note:

Current MCAP-£7.8m

“We continue to believe this ascribes almost no value to Fusion’s industry-leading antibody discovery/development technologies and suggest the shares offer a potentially highly geared return.”

The following quote is from CEO Adrian speaking at the investor presentation a few weeks ago.

Not only is this statement incredibly bullish for Fusions future, Adrians smile regarding his sleeves comment also shows his excitement and passion for the 'Step Changes' he has in the pipline.

'Positive development of optimal platform through the validation with the NCI really does position this company in a very enviable way for establishing commercial relationships, driving those revenues up and taking things forward. It will take time, these things in science always do, particulary in therapeutic research but we are in an extremely good position to deliver on that, and I'll leave you with a small teaser before we go to the questions in that there is more to come, there are a few more things up my sleeve than just arms.'

https://www.youtube.com/watch?v=h370dmBSjxM (Timestamp, Minute 38)

Stephen Smyth, CFO, in the investor presentation said that the full-year statutory accounts are being finalised, with interim revenues and margins already disclosed.

He also confirmed that the audited results will be released “by the end of the current quarter.”

Let's keep this board full of FAB related content please, this is not the school playground.

First:

AI checkers make mistakes,

The market leader Quillbot has this disclaimer on their website, 'Caution: Our AI Detector is advanced, but no detectors are 100% reliable, no matter what their accuracy scores claim. Never use AI detection alone to make decisions that could impact a person's career or academic standing'

Second:

Universities avoid using AI checkers to make decisions due to their lack of accuracy.

Third:

When you put VikRs post through it says 0% of this text is likely to be AI. :)

Another reminder even though it has been said before..

FAB is currently a touch over 7m MCAP!!!

Well said VikR,

Great to have a pharma professional on this board, who is also invested in FAB.

Well if we want to talk about staff, we have just hired another 4 employees.

This was posted on LinkedIN, Adrian commented, “There are some exciting times ahead and it's great to have you all with us.”

This was just last week.

Don't take my word for it, check it out for yourself!

https://www.linkedin.com/posts/fusion-antibodies-plc_welcomeback-teamfusion-newtalent-activity-7346872306670960640-EYn8/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAW5ZOwBC88ifeuk0zSYUM7K_p73b5NowQ4

Thanks Chris.

When you scroll down to the bottom it says April 2021 for first applications submitted.

When you click on the first document it shows signatures from November 2019.

This shows just how long Fusion have been going back forth with the patent office ensuring protection for their flagship product.

To think we are on the cusp of this exciting work being protected is amazing!

GTC you are a great asset to this board.

Chris, I haven't recently, do you mind dropping the link here?

Really pushing the boat out today ;)

Your consistent buying pattern (no matter how small) is to be respected!

Giants are known for their ravenous appetite, enjoy your lunch :)

Fusion Antibodies has woken up from a long nap, well rested and ready to take strong position in the antibody market.

PI's are taking position early this week before the 'step changes' (Adrian, CEO) start to flow.

As GTC has mentioned, Adrian has been buying on the open market, he know that good opportunities only come around rarely.

Combine that with a huge 490k share (32.5K GBP) buy on Monday morning that the MMs didn't want to print till after hours on Tuesday...

I will leave you with this quote from CEO Adrian, “Fusion Antibodies has a world class technology platform built over the last decade that has the potential to generate significant value and play a global role in the provision of high quality services to enhance the discovery and development of novel, effective antibody therapeutics.”

Like I said before the sleeping giant has woken up...

GLA

Smart money has just entered the fusion slingshot.

490k shares.

MMs must be low on shares to delay printing that trade from Monday morning.

All eyes on Fusion...

Great rise today, well done all holders.

Worth checking out FAB, could be in a very similar situation to OBD soon.

Only 7m MCAP.

GLA

OptiMAL is not just an incremental upgrade of their existing tech.

It’s a step-change in capability that can:

✅ Accelerate partner timelines.

✅ Improve the probability of clinical success.

✅ Command premium pricing.

✅ Enable licensing deals and future royalties.

✅ Differentiate Fusion in a crowded space.

This combination is what gives the platform the potential to drive significant revenue growth and create a more scalable, higher-margin business model over time.

OptiMAL has been proven to work independently validated by the US National Cancer Institute, arguably the most prestigious partner Fusion could have.

It’s now nearing patent protection in the largest global market, and the company is actively shaping the business model for a commercial launch.

Investors should get ready for what could be a genuine step change in Fusion’s growth trajectory.